XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic…
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
April 27, 2026 17:00 ET | Source: Cabaletta Bio PHILADELPHIA, April 27,…
Laigo Bio completes final close of oversubscribed seed financing of 17 million co-led by Biovance Capital and Kurma Partners to advance oncology and auto-immunity programs
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m…
Avid Organics to Launch the World’s First Commercial-Scale Bio-Based Glycolic Acid, AviGa Bio HP70, at in-cosmetics Global in Paris
AviGa™ Bio HP70 is a bio-based, 70% cosmetic-grade glycolic acid available globally…
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
March 17, 2026 22:46 ET | Source: SAB Biotherapeutics, Inc. MIAMI, March…
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
February 23, 2026 17:10 ET | Source: Kyntra Bio FG-3246 and enzalutamide…
Precise Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GREENSBORO, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Precise Bio, Inc. (“Precise…
Defeating the “Cold Chain” Barrier: Bio Usawa and Nanoly Bioscience Announce Strategic $500 Million Licensing Agreement for Breakthrough DynaShield Technology
SAN FRANCISCO and LOS ANGELES and KIGALI, Rwanda, Feb. 17, 2026 (GLOBE…
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
February 11, 2026 06:00 ET | Source: Upstream Bio – Verekitug provided…
